Henderson Group PLC cut its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 27.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 144,812 shares of the biopharmaceutical company’s stock after selling 55,431 shares during the period. Henderson Group PLC’s holdings in Bristol-Myers Squibb Company were worth $7,809,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Bank of Montreal Can bought a new stake in shares of Bristol-Myers Squibb Company during the second quarter worth $154,732,000. IBM Retirement Fund increased its stake in shares of Bristol-Myers Squibb Company by 1.1% in the second quarter. IBM Retirement Fund now owns 219,448 shares of the biopharmaceutical company’s stock worth $16,627,000 after buying an additional 2,421 shares during the period. Essex Investment Management Co. LLC increased its stake in shares of Bristol-Myers Squibb Company by 0.3% in the second quarter. Essex Investment Management Co. LLC now owns 225,829 shares of the biopharmaceutical company’s stock worth $16,610,000 after buying an additional 574 shares during the period. HL Financial Services LLC increased its stake in shares of Bristol-Myers Squibb Company by 0.8% in the second quarter. HL Financial Services LLC now owns 360,221 shares of the biopharmaceutical company’s stock worth $26,494,000 after buying an additional 2,901 shares during the period. Finally, PGGM Investments increased its stake in shares of Bristol-Myers Squibb Company by 1.3% in the second quarter. PGGM Investments now owns 1,321,858 shares of the biopharmaceutical company’s stock worth $97,223,000 after buying an additional 17,200 shares during the period. 68.81% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 56.22 on Friday. The firm has a 50-day moving average of $57.81 and a 200 day moving average of $59.73. The firm has a market cap of $93.96 billion, a PE ratio of 28.12 and a beta of 0.94. Bristol-Myers Squibb Company has a 52-week low of $49.03 and a 52-week high of $77.12.

Bristol-Myers Squibb Company (NYSE:BMY) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.12. The company earned $4.83 billion during the quarter, compared to analysts’ expectations of $4.76 billion. Bristol-Myers Squibb Company had a net margin of 18.54% and a return on equity of 28.98%. Bristol-Myers Squibb Company’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.39 earnings per share. On average, equities analysts predict that Bristol-Myers Squibb Company will post $2.86 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Stockholders of record on Friday, January 6th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend is Wednesday, January 4th. This is a boost from Bristol-Myers Squibb Company’s previous quarterly dividend of $0.38. Bristol-Myers Squibb Company’s payout ratio is presently 76.47%.

COPYRIGHT VIOLATION NOTICE: “Henderson Group PLC Sells 55,431 Shares of Bristol-Myers Squibb Company (BMY)” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at http://www.dailypolitical.com/2017/01/14/henderson-group-plc-sells-55431-shares-of-bristol-myers-squibb-company-bmy.html.

A number of brokerages have recently issued reports on BMY. Goldman Sachs Group, Inc. (The) cut shares of Bristol-Myers Squibb Company from a “strong-buy” rating to a “buy” rating and set a $75.00 price objective for the company. in a research note on Thursday, October 13th. Barclays PLC restated an “equal weight” rating on shares of Bristol-Myers Squibb Company in a research note on Wednesday, October 12th. Zacks Investment Research cut shares of Bristol-Myers Squibb Company from a “buy” rating to a “hold” rating in a research note on Monday, January 9th. Vetr cut shares of Bristol-Myers Squibb Company from a “strong-buy” rating to a “buy” rating and set a $62.28 price objective for the company. in a research note on Monday, December 12th. Finally, Evercore ISI restated a “hold” rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb Company in a research note on Sunday, January 8th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $65.89.

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.